Riverwater Partners LLC Boosts Stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Riverwater Partners LLC lifted its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 334.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 31,701 shares of the medical instruments supplier’s stock after acquiring an additional 24,401 shares during the quarter. LeMaitre Vascular accounts for about 1.4% of Riverwater Partners LLC’s holdings, making the stock its 11th largest position. Riverwater Partners LLC owned about 0.14% of LeMaitre Vascular worth $2,885,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. CANADA LIFE ASSURANCE Co boosted its stake in LeMaitre Vascular by 44.7% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 22,252 shares of the medical instruments supplier’s stock worth $1,472,000 after purchasing an additional 6,875 shares during the period. Quantbot Technologies LP lifted its position in LeMaitre Vascular by 1,001.4% in the 1st quarter. Quantbot Technologies LP now owns 7,335 shares of the medical instruments supplier’s stock worth $487,000 after buying an additional 6,669 shares during the last quarter. Vanguard Group Inc. boosted its stake in LeMaitre Vascular by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier’s stock worth $87,914,000 after buying an additional 38,303 shares in the last quarter. Quadrature Capital Ltd lifted its holdings in shares of LeMaitre Vascular by 129.4% in the 1st quarter. Quadrature Capital Ltd now owns 22,432 shares of the medical instruments supplier’s stock worth $1,484,000 after acquiring an additional 12,654 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its stake in shares of LeMaitre Vascular by 554.7% in the 1st quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier’s stock valued at $3,697,000 after purchasing an additional 47,218 shares in the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on LMAT shares. Barrington Research restated an “outperform” rating and set a $92.00 price target on shares of LeMaitre Vascular in a research report on Friday, September 20th. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Cantor Fitzgerald started coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price objective on the stock. JMP Securities raised their target price on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 20th. Finally, Lake Street Capital assumed coverage on LeMaitre Vascular in a report on Friday, August 2nd. They issued a “buy” rating and a $105.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, LeMaitre Vascular presently has an average rating of “Moderate Buy” and a consensus target price of $94.67.

Insiders Place Their Bets

In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of LeMaitre Vascular stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total value of $251,380.41. Following the sale, the director now owns 14,114 shares of the company’s stock, valued at $1,158,335.98. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 10.79% of the company’s stock.

LeMaitre Vascular Stock Performance

Shares of LMAT opened at $86.97 on Thursday. The firm’s 50-day simple moving average is $89.22 and its two-hundred day simple moving average is $81.97. LeMaitre Vascular, Inc. has a fifty-two week low of $44.27 and a fifty-two week high of $93.32. The stock has a market cap of $1.95 billion, a PE ratio of 57.60, a price-to-earnings-growth ratio of 2.45 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. The business had revenue of $55.85 million during the quarter, compared to analyst estimates of $54.98 million. LeMaitre Vascular had a return on equity of 12.41% and a net margin of 18.33%. The company’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.37 EPS. Equities research analysts predict that LeMaitre Vascular, Inc. will post 1.85 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, August 29th. Investors of record on Thursday, August 15th were paid a dividend of $0.16 per share. The ex-dividend date was Thursday, August 15th. This represents a $0.64 annualized dividend and a yield of 0.74%. LeMaitre Vascular’s payout ratio is 42.38%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.